Please login to the form below

Not currently logged in
Email:
Password:

OncoVex

This page shows the latest OncoVex news and features for those working in and with pharma, biotech and healthcare.

AZ signs yet another cancer immunotherapy deal

AZ signs yet another cancer immunotherapy deal

The most advanced is Amgen's OncoVex (talimogene laherparepvec), which in 2013 became the first oncolytic virus to show efficacy in a phase III trial involving people with the skin cancer

Latest news

  • Amgen says viral melanoma therapy clears phase III trial Amgen says viral melanoma therapy clears phase III trial

    Amgen says viral melanoma therapy clears phase III trial. OncoVex demonstrates durable response in skin cancer patients. ... The melanoma immunotherapeutic - talimogene laherparepvec (also known as OncoVex) - works by introducing a virus that selectively

  • Disease focus: Melanoma

    nilotinib. In development. Vaccines. OncoVEX GM-CSF. In development. Vaccines. MAGE-A3 ASCI.

  • Amgen to buy BioVex

    BioVex's portfolio includes OncoVex (GM-CSF) – an investigational vaccine to treat melanoma and head and neck cancer. ... Philip Astley-Sparke, CEO, BioVex, also praised the agreement: "Amgen is ideally positioned to leverage the potential of OncoVEX

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics